Evidence map›Paper›PMID 36748330›Full record

ArticleActa dermato-venereologica2023

Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma.

Kalle Mattila, Helmi Vihinen, Antti Karlsson, Heikki Minn, Pia Vihinen, Eetu Heervä

Open access · goldAbstract read
In one paragraph

Article in Acta dermato-venereologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Sun protection behaviors, healthcare access, and smoking among melanoma survivors.Journal of cancer survivorship : research and practice · 2026
    Article
  4. Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kalle MattilaDepartment of Oncology and FICAN West Cancer Centre, Turku University Hospital and University of Turku, Turku, Finland; InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Helmi VihinenTurku School of Economics, University of Turku, Turku, Finland.
Antti KarlssonAuria Biobank and Turku University Hospital, Turku Finland.
Heikki MinnDepartment of Oncology and FICAN West Cancer Centre, Turku University Hospital and University of Turku, Turku, Finland.
Pia VihinenDepartment of Oncology and FICAN West Cancer Centre, Turku University Hospital and University of Turku, Turku, Finland.
Eetu HeerväDepartment of Oncology and FICAN West Cancer Centre, Turku University Hospital and University of Turku, Turku, Finland. eetu.heerva@tyks.fi.
University of Turku · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have suggested that persistent tobacco smoking impairs survival in cutaneous melanoma, but the effects of smoking and other prognostic factors have not been described in detail. This study examined the association of smoking (persistent, former, or never) with melanoma-specific (MSS) and overall survival (OS) in patients with cutaneous melanoma treated in Southwest Finland during 2005 to 2019. Clinical characteristics were obtained from electronic health records for 1,980 patients. Smoking status was available for 1,359 patients. Patients were restaged according to the 8th edition of the tumour-node-metastasis (TNM) classification. Smoking remained an independent prognostic factor for inferior melanoma-specific survival regardless of age, sex, stage, and comorbidities. The hazard ratio of death from melanoma was 1.81 (1.27-2.58, p = 0.001) in persistent and 1.75 (1.28-2.40, p = 0.001) in former smokers compared with never smokers. In 351 stage IV patients, smoking was associated with increased melanoma-specific and overall mortality: median MSS 10.4 (6.5-14.3), 14.6 (9.1-20.1), and 14.9 (11.4-18.4) months, p = 0.01 and median OS 10.4 (6.5-14.3), 13.9 (8.6-19.2), and 14.9 (11.7-18.1) months, p = 0.01 in persistent, former, and never smokers, respectively. In conclusion, since smoking represents an independent modifiable poor prognostic factor in patients with cutaneous melanoma, smoking habits should be proactively asked about by healthcare professionals, in order to support smoking cessation.

Indexed as

MelanomaSkin NeoplasmsCutaneous Malignant MelanomaHumansNeoplasm StagingPrognosisRetrospective StudiesSmokingTobacco Smoking

Identifiers

PMID36748330
PMCPMC10391787
OpenAlexW4319333635

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.